Αναζήτηση Δραστικών

RITUXIMAB

ATC

Εμπορικές Ονομασίες

  • MABTHERA
    Μορφές: C/S.SOL.IN
    Μορφές:
    Μορφές: INJ.SOL
  • DRUGBANK - Rituximab
  • indication:

    For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

  • pharmacology:

  • mechanism:

    The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.

  • toxicity:

  • absorprion:

  • halflife:

    0.8 hours (mammalian reticulocytes, in vitro)

  • roouteelimination:

  • volumedistribution:

    * 3.1 L

  • clearance:

    * 0.34 L/day [RA patients]